Price
Target price
-
-
-
-
-
?3.58
WKN: A3DM91 / Symbol: CASI / Name: CASI Pharmaceuticals Inc. / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
CASI Pharmaceuticals Inc. Stock
Our community is currently high on CASI Pharmaceuticals Inc. with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 3 € shows a very positive potential of 88.68% compared to the current price of 1.59 € for CASI Pharmaceuticals Inc..
For the coming years our community has positive and negative things to say abot the CASI Pharmaceuticals Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Customer and product portfolio" there were negative voices in the community.
Pros and Cons of CASI Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CASI Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | -2.020% | 13.033% | 33.509% | 25.076% | 33.836% | 124.560% | 3.920% |
| Evolus Inc | -2.830% | -5.936% | -30.169% | -69.023% | -24.404% | -56.859% | -30.217% |
| Champions Oncology Inc | -3.390% | -5.000% | -3.390% | -46.226% | -1.724% | 54.054% | -39.683% |
Comments
CASI Pharmaceuticals (NASDAQ:CASI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its price target lowered by analysts at HC Wainwright from $6.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CASI provided by MarketBeat